HIV / AIDS

In our latest podcast, Elizabeth Marlowe, PhD, D(ABMM), discusses the findings of Quest Diagnostics' large US HIV testing study, which showed a significant decline in HIV drug resistance across major antiretroviral classes, reflecting the impact of modern high-barrier therapies and improved viral suppression.

Merck’s investigational once-daily, 2-drug HIV regimen, doravirine/islatravir, achieved its primary efficacy and safety end points in a phase 3 trial.

Gilead reports its investigational single tablet of bictegravir and lenacapavir was efficacious in people with HIV who are virologically suppressed and who switched from taking multitablet regimens. The company says its phase 3 study results will form the basis for its future regulatory submissions.

At IDWeek, Jean van Wyk, MBChB, MFPM, chief medical officer at ViiV Healthcare, discussed the 96-week results from the PASO DOBLE study and the preliminary long-acting injectable PrEP results from the CLARITY study.

New 96-week results from the study show that Dovato is as effective as Biktarvy in maintaining viral suppression in adults with HIV, while leading to less weight gain and fewer drug-related adverse events.

Initial findings from the phase 1 CLARITY study offer the first direct comparison of the acceptability and tolerability of single-dose cabotegravir and lenacapavir long-acting injections in HIV-negative adults, revealing differences in patient and health care provider preferences.

This newly approved long-acting injectable PrEP offers 6 months of HIV protection, and represents a major scientific and policy breakthrough. However, its success will depend on ensuring equitable access, enforcing coverage requirements, and maintaining a robust, multi-faceted HIV prevention infrastructure amid political and systemic challenges.

Nimish Patel, PharmD, discusses UC San Diego’s care offerings in HIV, the challenges of getting care to marginalized populations, and what the addition of lenacapavir means to individuals looking to access PrEP.

Today’s MMWR recommends twice-yearly subcutaneous lenacapavir for people ≥35 kg, citing PURPOSE-1/2 efficacy, a favorable safety profile with mostly mild to moderate injection-site reactions, and potential adherence benefits.

William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.

Up to 2 million people in low- and lower-middle-income countries may gain access to the long-acting PrEP option under a three-year, no-profit agreement.

David Margolis, MD discusses his team’s work at UNC looking at combination treatment that includes the cancer drug, vorinostat, and immunotherapy as a potential HIV cure.

WHO and HRP highlight new research on HIV communication, STI priorities, and inclusive strategies to strengthen sexual health worldwide.

UNC’s Sarah Rutstein, MD, PhD, discusses her research uncovering the inability of some people to receive HIV prevention medication in both the US and Africa and strategies to address it.

This review highlights how people living with HIV are living longer due to antiretroviral therapy but face unique age-related health challenges, including cardiovascular disease, metabolic syndrome, renal dysfunction, neurocognitive decline, immunosenescence, bone loss, and frailty, requiring tailored screening and management strategies.

A long-acting HIV-1 capsid inhibitor demonstrates over 99% efficacy, paving the way for expanded access to adults and adolescents across the EU and low-income countries.

Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.

This investigational two-drug regimen for treatment of adults with virologically suppressed HIV was given a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

Grace Kulik, PT, DPT, discusses key risk factors and the role of inflammation, ART, and screening in preserving mobility among aging individuals with HIV.

6–3 ruling preserves no-cost insurance coverage for preventive services such as HIV PrEP, contraceptives, and screenings.

Gilead’s Yeztugo, a long-acting HIV capsid inhibitor, shows 96 to 100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support programs.

A coalition of over 100 US companies is supporting the federal initiative to end the HIV epidemic by 2030, but legal and funding threats now jeopardize this progress and the significant health and economic benefits it promises.

As the cohort of people living with HIV in the US ages, HIV care programs must rapidly adapt to the changing needs of older adults with HIV.